Year 2019 / Volume 111 / Number 9
Editorial
Treating Helicobacter pylori infection in the face of growing antibiotic resistance

653-654

DOI: 10.17235/reed.2019.6575/2019

Luis Fernández Salazar, Julio Valle Muñoz,

Abstract
Helicobacter pylori eradication cures most peptic ulcers and non-atrophic chronic gastritis, and may potentially prevent over 70% of gastric cancers. In the late 1980s, shortly after the discovery of H. pylori, eradication therapy was established based on the use of two antibiotics (amoxicillin and clarithromycin) and one proton-pump inhibitor for 7 or 10 days (OCA7, OCA10). This therapy, recommended during the first Maastricht Consensus Conference, obtained eradication rates above 90%, and was equally effective everywhere around the world. However, over time, H. pylori has developed resistance to several antibiotics.
Share Button
New comment
Comments

10/03/2021 23:20:46
estoy realizando un estudio en mi laboratorio clinico con respecto a la bacteria helicobacter pylori necesito su colaboracion soy salvadoreno


10/03/2021 23:18:28
estoy realizando un estudio en mi laboratorio clinico con respecto a la bacteria helicobacter pylori necesito su colaboracion soy salvadoreno


12/09/2019 4:50:01
ESTOY INTERESADO EN RECIBIR MAS INFOMACION , TENEMOS ALTA INCIDENCIA DE RESISTENCIA AL PLAN CONVENCIONAL -SOY MEDICO GSTROENTEROLOGO


References
1. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99:1833-55.
2. Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, GrahamDY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016; 150:1113-1124.
3. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41:8-13.
4. Megraud F. Antibiotic Resistance: The Key Element to Consider in Helicobacter pylori Treatment. Gastroenterology 2018; 155:1300-1302.
5. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions. Gastroenterology 2018; 155:1372-1382.
6. Park CG, Kim S, Lee EJ, Jeon HS, Han S. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: A prospective, observational study. Medicine (Baltimore) 2018; 97: e11835. doi: 10.1097/MD.0000000000011835.
7. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology 2019; 157:44-53.
8. Megraud F, Coenen S, Versporten A Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34–42.
9. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005; 100:2083-99.
10. Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018; 23(1). doi: 10.1111/hel.12452. Epub 2017 Nov 26.
11. Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol. 2019; 114:900-906.
12. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66:6-30.
13. O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018; 23: Suppl 1: e12519. doi: 10.1111/hel.12519.
14. Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current Status of the Third-Line Helicobacter pylori Eradication. Gastroenterol Res Pract 2018; 2018:6523653. doi: 10.1155/2018/6523653. eCollection 2018.
15. Valle-Muñoz J, Muñoz-Gómez P, Sierra-Bernal C, de Andrés E, Gómez-Hernando C, Gómez-Rodríguez R. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Rev Esp Enferm Dig 2019. doi: 10.17235/reed. 2019.6198/2019.
16. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151:51-69.
17. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212-239.
Related articles

Special Article

V Spanish Consensus Conference on Helicobacter pylori infection treatment

DOI: 10.17235/reed.2021.8358/2021

Letter to the Editor

A question about dyspeptic patients analyzed using psychometric scores

DOI: 10.17235/reed.2017.5401/2017

Letter to the Editor

Acute psychotic episode secondary to Helicobacter pylori eradication treatment

DOI: 10.17235/reed.2017.4482/2016

Citation tools
Fernández Salazar L, Valle Muñoz J. Treating Helicobacter pylori infection in the face of growing antibiotic resistance. 6575/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1536 visits.
This article has been downloaded 528 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 17/08/2019

Accepted: 20/08/2019

Online First: 03/09/2019

Published: 05/09/2019

Article Online First time: 17 days

Article editing time: 19 days


Share
This article has been rated by 3 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology